Virttu Biologics Shows Robust Evidence Of Immunological Activity In Mesothelioma Patients Following SEPREHVIR® Administration Results To Be Presented At Society For ImmunoTherapy Of Cancer (SITC)

- Clinical data from mesothelioma patients identifies evidence of immunological efficacy with robust Th1 cytokine responses post SEPREHVIR administration

- Preclinical data on enhanced systemic targeted delivery demonstrates that SEPREHVIR arming of the magnetic macrophage carriers converts them from benign to aggressive, anti-cancer types.

Nov 05, 2015, 05:06 ET from Virttu Biologics